‹ Back

Novo Nordisk Partners with OpenAI to Speed Drug Discovery

 

Novo Nordisk and OpenAI announce a strategic AI partnership to accelerate drug discovery, spanning R&D, manufacturing, and global operations.

 

 

Novo Nordisk Taps OpenAI to Accelerate Drug Development Pipeline

 

Novo Nordisk announced on April 14, 2026, a strategic partnership with OpenAI that will deploy artificial intelligence across the Danish pharmaceutical company's global operations, from early-stage drug discovery through manufacturing, supply chain management, and commercial functions.

 

The collaboration has been structured with strict data protection, governance, and human oversight to ensure ethical and compliant use. No financial terms were disclosed.

 

The partnership will apply advanced AI capabilities to analyse complex datasets, identify promising drug candidates, and reduce the time required to move from research to patient. Pilot programmes will begin across research and development, manufacturing, and commercial operations, with full integration planned by the end of 2026.

 

Mike Doustdar, president and chief executive officer of Novo Nordisk, framed the collaboration as central to the company's long-term competitive strategy. "This partnership is one important step in positioning Novo Nordisk to lead in the next era of healthcare.

 

There are millions of people living with obesity and diabetes who need treatment options, and we know there are therapies still waiting to be discovered that could change their lives," Doustdar said. He added that integrating AI would enable the company to analyse datasets at a previously impossible scale, identify patterns that human researchers could not, and test hypotheses at greater speed.

 

Sam Altman, chief executive officer of OpenAI, said the collaboration extends beyond scientific research. "AI is reshaping industries and in life sciences, it can help people live better, longer lives. This collaboration with Novo Nordisk will help them accelerate scientific discovery, run smarter global operations, and redefine the future of patient care," Altman said.

 

Workforce Upskilling and Operational Scope

 

OpenAI will assist Novo Nordisk in upskilling the company's global workforce and enhancing AI literacy. Novo Nordisk emphasised that the aim is not to replace its scientists, but to "supercharge" them by increasing their productivity and reducing the need for future hiring. The company employs approximately 68,800 people across 80 countries.

 

The partnership will also apply OpenAI's capabilities to improve efficiency in manufacturing, supply chain and distribution, as well as corporate operations. The scope of the integration makes this one of the most expansive pharma-AI partnerships announced to date, reaching from laboratory benches to logistics networks within a single agreement.

 

Existing AI Infrastructure Underpins the Push

 

The OpenAI deal builds on an already established technology foundation at Novo Nordisk. The move builds on Novo's current AI initiatives, which also include a collaboration with Nvidia to use the Gefion sovereign AI supercomputer to "accelerate drug discovery efforts through innovative AI use cases." The companies said last year that they aim to create customised AI models and agents that Novo can use for early research and clinical development.

 

In 2024, the Novo Nordisk Foundation partnered with Nvidia and the Export and Investment Fund of Denmark (EIFO) to establish the Danish Centre for AI Innovation, which operates Gefion — Denmark's first AI-ready supercomputer. The OpenAI partnership layers a broader operational AI deployment onto that existing research-focused infrastructure.

 

Pharma AI Deals Surge as Obesity Drug Race Intensifies

 

The announcement arrives as artificial intelligence investment in the pharmaceutical sector has accelerated sharply. According to GlobalData's Pharmaceutical Intelligence Center, the total value of AI partnerships took a 120% year-on-year uptick between 2024 and 2025. Venture financing deals in the life sciences sector also saw a 48% increase in 2025 compared with the previous year.

 

Novo Nordisk is one of several pharmaceutical companies to forge an alliance with OpenAI in recent years, with players including Sanofi, Moderna, Thermo Fisher Scientific, and Eli Lilly also having inked deals with the company.

 

Novo Nordisk is locked in a race with U.S. rival Eli Lilly for dominance in the lucrative weight-loss market, in which it has lost its first-mover advantage. Eli Lilly has signed 16 AI-based deals since 2025, with notable examples being its $1 billion partnership with Nvidia and a $2.75 billion deal with Insilico Medicine, according to GlobalData's Pharmaceutical Intelligence Center. Eli Lilly announced a partnership with Insilico Medicine in March 2026 to develop and commercialise medicines discovered using artificial intelligence.

 

Novo is trying to claw back market share through its Wegovy pill, launched in January, and next-generation drugs. The OpenAI partnership represents the company's most sweeping attempt yet to use technology infrastructure as a competitive lever across its entire business, from molecule identification to global commercial deployment.